Otros idiomas Brainstorm Cell Therapeutics Inc.

Acciones

BCLI

US10501E2019

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 07/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,368 ^USD	-1,60 %		-2,52 %	+34,80 %

17/04	Brainstorm Cell Therapeutics Inc. anuncia el cese de Stacy Lindborg como codirectora ejecutiva a partir del 9 de mayo de 2024	CI
17/04	Brainstorm Cell Therapeutics Inc. anuncia cambios en la dirección	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024	17/04
Brainstorm Cell Therapeutics Inc. Announces Management Changes	17/04
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule	11/04
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment for Phase 3b Trial in ALS	10/04
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS	10/04
Brainstorm Cell Therapeutics Says FDA Agrees on Design of Phase 3B ALS Trial	09/04
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS	09/04
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS	09/04
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program	08/04
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update	01/04
North American Morning Briefing : Stocks Set for -2-	28/03
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference	28/02
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference	27/02
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS	26/02
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS	23/02
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS	23/02
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum	13/02
Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline	02/01
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm	31/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Brainstorm Cell Therapeutics Inc.

Acciones

BCLI

US10501E2019

Otros idiomas

Filtros